Figure 4
From: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Westernblot analysis of phospho-P70S6kinase in cisplatin resistant cells. A: SR-2 cells. Lane 1. SR-2 treated with cisplatin 10 ug/ml and CCI-779 150 ng/ml, lane 2: SR-2 treated with CCI-779 at 150 ng/ml. Both 1&2 showed only minimal amount of phospho-p70S6kinase. Lane 3&4 SR-2 treated with cisplatin at 0.1 and 10 ug/ml., cisplatin does not affect the amount of phospho-p70S6kinase and showed similar intensity to control cells. Lane 5: control untreated cells. B. SCLCBC cells. Lane 1: Control untreated cells, lane 2&3 SCLCBC treated with cisplatin at 0.1 and 10 ug/ml respectively. Similar amounts of phospho-p70S6kinase were seen. Lane 4 SCLCBC treated with cisplatin 10 ug/ml and CCI-779 150 ng/ml. The amount of phosphor-p70S6kinase is less. Lane 5 SCLCBC treated with CCI-779 at 150 ng/ml. No signal intensity for p-70S6kinase was seen. Actin was used as control for protein loading.